Targeting Migration, Survival and Immune-response Pathways In cancer

The Biokine Story

Biokine Therapeutics is a private biopharmaceutical company founded in 2000. Biokine lead product BKT140/BL8040, is a high affinity, long-acting CXCR4 receptor inhibitor that already passed successful Phase III for Stem Cell Mobilization and Phase I/II for Immunotherapy for cancer together with immune check point inhibitor Pembrolizumab (Keytruda, Merck) and Atezolizumab (Tecentriq, Genentech/Roche). BL8040 was licensed to BiolineRx and is being developed in the clinic together with BiolineRx Ltd. (NASDAQ:BLRX). Biokine pipeline also include BKT300 which was Identified, Biokine’s Might™ phenotypic screen. BKT300 is a first in class small molecule that specifically controls migration and survival pathways in cancer cells via targeting the protein regulator of cytokinesis 1 (PRC1) , a novel less explored target.  BKT-300 is in IND enabling studies, 12 months to IND-submission. Phase I/II dose-finding study, will evaluate its safety and initial efficacy in patients with aggressive solid tumors that have high expression of Ki67 and CDC25c. BKT-300 has a strong worldwide IP coverage (life span till 2042) including composition and method of use patents. Biokine has also developed a suite of unique technologies, MigHit™ – which is a phenotypic screen that allows identification of small molecules targeting migration and survival pathways in cancer and ImmunHit™ which is platform technology enables identification of small molecules targeting IFN-g mediated immune response in cancer and inflammation.

Our Mission

temp-visionThe mission of Biokine is devoted to identifying novel molecular and cellular mechanisms that regulate tumor development and metastasis and to develop novel therapeutics against these devastating diseases.

Why Cancer?

According to estimates from the International Agency for Research on Cancer (IARC), there were 12.7 million new cancer cases in 2008 worldwide,of which 5.6 million occurred in economically developed countries and 7.1 million in economically developing countries. The corresponding estimates for total cancer deaths in 2008 were 7.6 million (about 21,000 cancer deaths a day), 2.8 million in economically developed countries and 4.8 million in economically developing countries. By 2030, the global burden is expected to grow to 21.4 million new cancer cases and 13.2 million cancer deaths simply due to the growth and aging of the population, as well as reductions in childhood mortality and deaths from infectious diseases in developing countries.
In 2014, there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US. Cancer remains the second most common cause of death in the US, accounting for nearly 1 of every 4 deaths.
Global Cancer Facts & Figures   www.cancer.org

Recent News